4basebio PLC H1 2021 Half-Year Results - DNA Synthesis & Gene Therapy

4basebio PLC reports H1 2021 interim results, highlighting conversion to PLC status and progress toward completing a DNA manufacturing facility by year-end. The specialist life sciences company, focused on synthetic DNA and non-viral vectors for cell and gene therapies, demonstrates positive validation studies comparing its DNA to plasmid DNA and secures multiple collaboration agreements.